In contrast, modern GLP-1 receptor agonists and dual incretin agonists have demonstrated clinically meaningful and sustained reductions in body weight, with additional benefits on glycemic control and cardiometabolic risk markers
Translational insights into stem cell preconditioning: from molecular mechanisms to preclinical applications
These numbers come from the SURMOUNT-1 trial, which enrolled over 2,500 adults with obesity or overweight and tracked outcomes for 72 weeks
In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period
I'm checking in
(8) A V Schally, X Zhang, R Cai, J M Hare, R Granata, and M Bartoli (2019) Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists Endocrinology, 2019 Jul 1, Volume 160 (Issue 7), Pages 1600-1612